ArticleAnnals of clinical and translational neurology2026
microRNA-7-5p and α-Synuclein SAA Predict Parkinson's Disease Phenoconversion.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCorroborate blood neuron-derived extracellular vesicle (NDEV) alpha-synuclein (αSyn), the CSF αSyn seed amplification assay (αSyn-SAA), and blood microRNA-7-5p (miR-7-5p) as markers for Parkinson's disease (PD) phenoconversion and determine if combining these markers would help select subjects who would be more likely to phenoconvert.
methodsUsing Parkinson Progression Marker Initiative data, time to PD phenoconversion was determined by Hoehn and Yahr scores. Log-rank analysis was used to find cutpoints. Cox regression analysis was used with log[miR-7-5p], log[NDEV αSyn], and the αSyn-SAA. Models included age and sex.
resultsIn a Cox model with baseline log[miR-7-5p], for each unit increase in log[miR-7-5p], there was 1.57 times increased PD phenoconversion (p = 0.003). In a model with baseline log[NDEV αSyn], only baseline age was associated with increased phenoconversion (p < 0.05). Using Cox regression analysis, the cutpoints for miR-7-5p and NDEV αSyn were 27.39 reads per million mapped (p < 0.01) and 18.36 pg/mL (p = 0.01), respectively. In separate models using log[miR-7-5p] and log[NDEV αSyn] cutpoints, higher levels of log[miR-7-5p] and log[NDEV αSyn] resulted in 2.26 (p < 0.001) and 4.46 (p < 0.05) times increased PD phenoconversion, respectively. A positive αSyn-SAA was associated with 3.62 times increased phenoconversion (p < 0.001). Having log[miR-7-5p] higher than its cutpoint and a positive αSyn-SAA was associated with 4.31 times phenoconversion (p < 0.001).
interpretationBlood miR-7-5p, NDEV αSyn, and αSyn-SAA could be used to enrich for prodromal patients likely to develop PD earlier in disease-modifying clinical trials and combining them could further enrich for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.